256 related articles for article (PubMed ID: 21787192)
1. Pharmacogenomics of cisplatin-induced ototoxicity.
Mukherjea D; Rybak LP
Pharmacogenomics; 2011 Jul; 12(7):1039-50. PubMed ID: 21787192
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
[TBL] [Abstract][Full Text] [Related]
3. Challenges in interpreting the evidence for genetic predictors of ototoxicity.
Ratain MJ; Cox NJ; Henderson TO
Clin Pharmacol Ther; 2013 Dec; 94(6):631-5. PubMed ID: 24241639
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
5. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
Hagleitner MM; Coenen MJ; Patino-Garcia A; de Bont ES; Gonzalez-Neira A; Vos HI; van Leeuwen FN; Gelderblom H; Hoogerbrugge PM; Guchelaar HJ; Te Loo MW
PLoS One; 2014; 9(12):e115869. PubMed ID: 25551397
[TBL] [Abstract][Full Text] [Related]
6. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
[TBL] [Abstract][Full Text] [Related]
7. [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
Mironovich OL; Bliznetz EA; Garbaruk ES; Belogurova MB; Subora NV; Varfolomeeva SR; Kachanov DY; Shamanskaya TV; Markova TG; Polyakov AV
Vestn Otorinolaringol; 2018; 83(4):60-66. PubMed ID: 30113582
[TBL] [Abstract][Full Text] [Related]
8. Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC; Ross CJ; Pussegoda K; Bhavsar AP; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
Clin Pharmacol Ther; 2014 Sep; 96(3):296-8. PubMed ID: 25141953
[TBL] [Abstract][Full Text] [Related]
9. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
[TBL] [Abstract][Full Text] [Related]
10. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC; Ross CJ; Bhavsar AP; Amstutz U; Pussegoda K; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
Clin Pharmacol Ther; 2014 Mar; 95(3):253. PubMed ID: 24193170
[No Abstract] [Full Text] [Related]
11. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.
Lanvers-Kaminsky C; Ciarimboli G
Pharmacogenomics; 2017 Dec; 18(18):1683-1695. PubMed ID: 29173064
[TBL] [Abstract][Full Text] [Related]
12. [Genetic background of cisplatin induced ototoxicity].
Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.
Lanvers-Kaminsky C; Malath I; Deuster D; Ciarimboli G; Boos J; Am Zehnhoff-Dinnesen AG
Clin Pharmacol Ther; 2014 Aug; 96(2):156-7. PubMed ID: 24642735
[No Abstract] [Full Text] [Related]
14. Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
Carleton BC; Ross CJ; Bhavsar AP; Lee JW; Visscher H; Rassekh SR; Hayden MR
Clin Pharmacol Ther; 2014 Aug; 96(2):158. PubMed ID: 24755913
[No Abstract] [Full Text] [Related]
15. Genetics of cisplatin ototoxicity: confirming the unexplained?
Boddy AV
Clin Pharmacol Ther; 2013 Aug; 94(2):198-200. PubMed ID: 23872836
[TBL] [Abstract][Full Text] [Related]
16. Genetic risk factors of cisplatin induced ototoxicity in adult patients.
Talach T; Rottenberg J; Gal B; Kostrica R; Jurajda M; Kocak I; Lakomy R; Vogazianos E
Neoplasma; 2016; 63(2):263-8. PubMed ID: 26774148
[TBL] [Abstract][Full Text] [Related]
17. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
[TBL] [Abstract][Full Text] [Related]
18. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
Yang JJ; Lim JY; Huang J; Bass J; Wu J; Wang C; Fang J; Stewart E; Harstead EH; E S; Robinson GW; Evans WE; Pappo A; Zuo J; Relling MV; Onar-Thomas A; Gajjar A; Stewart CF
Clin Pharmacol Ther; 2013 Aug; 94(2):252-9. PubMed ID: 23820299
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z
Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853
[TBL] [Abstract][Full Text] [Related]
20. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
Lee JW; Pussegoda K; Rassekh SR; Monzon JG; Liu G; Hwang S; Bhavsar AP; Pritchard S; Ross CJ; Amstutz U; Carleton BC;
Ther Drug Monit; 2016 Aug; 38(4):423-31. PubMed ID: 26960170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
